LongBio Pharma receives FDA IND clearance for LP-003, its investigational anti-IgE antibody, enabling U.S. clinical trials for peanut allergy.
Written By: Rishabh Sonawane, BPharm
Reviewed By: Pharmacally Editorial Team
LongBio Pharma has announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for LP-003, the company’s investigational novel-sequence anti-IgE monoclonal antibody for the treatment of peanut allergy. The authorization permits the initiation of U.S. clinical trials, marking a key regulatory milestone in the global clinical development of LP-003 and expanding its clinical evaluation beyond China.
FDA IND Approval for Peanut Allergy
The FDA’s IND clearance enables LongBio Pharma to initiate clinical studies of LP-003 in patients with peanut allergy in the United States. The approval represents an important advancement in the company’s international regulatory strategy and supports the continued global clinical development of the investigational biologic for IgE-mediated allergic diseases. Data generated from the U.S. clinical program are expected to support the ongoing development of LP-003.
Clinical Significance in Peanut Allergy
Peanut allergy is one of the most severe forms of food allergy because even minimal exposure can trigger life-threatening allergic reactions, including anaphylaxis. Food allergy affects a growing global population, with the number of patients increasing from 273.2 million in 2018 to 361.8 million in 2024 and projected to reach 456.7 million by 2030. The increasing prevalence highlights a substantial unmet medical need for targeted therapies that address the underlying immunological mechanisms of allergic disease.
Clinical Profile of LP-003
LP-003 is an investigational novel-sequence anti-IgE monoclonal antibody being developed for peanut allergy and other IgE-mediated diseases, including seasonal allergic rhinitis, chronic spontaneous urticaria (CSU), allergic asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). Anti-IgE therapy is an established biologic treatment strategy for several allergic disorders and has been included in Chinese clinical practice guidelines for the diagnosis and treatment of seasonal allergic rhinitis and CSU.
Mechanism of Action of LP-003
LP-003 binds circulating free immunoglobulin E (IgE), preventing its interaction with the high-affinity FcεRI receptor on immune cells. By blocking this key IgE-mediated pathway, the antibody inhibits the Type I hypersensitivity cascade that underlies allergic reactions, thereby reducing IgE-driven immune responses. IgE is a central driver of Type I hypersensitivity reactions responsible for multiple allergic diseases, including peanut allergy, allergic asthma, seasonal allergic rhinitis, and chronic spontaneous urticaria.
Global Clinical Development Program
LongBio Pharma has already received regulatory approvals and initiated clinical trials for LP-003 in China across multiple allergic disease indications, including seasonal allergic rhinitis, chronic spontaneous urticaria, allergic asthma, chronic rhinosinusitis with nasal polyps, and food allergy. The FDA IND authorization expands the company’s global clinical development program by enabling evaluation of LP-003 in U.S. patient populations.
Regulatory Path Froward
The FDA’s IND approval marks a significant regulatory milestone in the global clinical development of LP-003, enabling the initiation of U.S. clinical trials for peanut allergy. The upcoming studies are expected to evaluate the clinical profile of LP-003 while generating important evidence to support future stages of development. As the program advances, these data will help define the therapy’s potential as a targeted treatment option for patients with peanut allergy and other IgE-mediated allergic diseases.
Reference
About the Writer
Rishabha Sonawane, B.Pharm (LinkedIn) is healthcare writer with a strong interest in medical writing, regulatory affairs, clinical research, and AI-driven drug discovery. He has completed specialized training from the NIH and ICMR in clinical pharmacology, clinical research, and scientific writing. Passionate about evidence-based healthcare communication, he focuses on translating complex scientific research into clear, accurate, and engaging medical content.